文献速递消化系统肿瘤

在计划接受结直肠癌肝转移局部治疗的患者中,CT之外加做MRI(CAMINO):一项国际、多中心、前瞻性诊断准确性试验

MRI in addition to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO): an international, multicentre, prospective, diagnostic accuracy trial.
PubMed 文献 · Lancet Oncol · 2023-12-08

CAMINO是一项国际多中心前瞻性诊断准确性试验,纳入298例基于增强CT计划接受局部治疗的结直肠癌肝转移患者,评估加做肝增强MRI(含弥散加权成像和钆塞酸二钠)后局部治疗计划改变的比例。结果显示92例(31%;95% CI 26-36)因MRI改变治疗计划。作者认为,所有基于增强CT计划局部治疗的结直肠癌肝转移患者均应考虑肝增强MRI。

要点

  • 基于增强CT计划局部治疗的结直肠癌肝转移患者中,加做肝增强MRI后31%(95% CI 26-36)的患者局部治疗计划发生改变。
  • 改变包括40例(13%)需更广泛局部治疗、11例(4%)需更小范围局部治疗、34例(11%)撤销治愈性局部治疗指征。
  • 撤销指征的34例中,26例(9%)为病变过广泛,8例(3%)为肝增强MRI显示良性病变(中位随访21.0个月确认)。

核心结论

  • 作者认为,所有基于增强CT计划接受局部治疗的结直肠癌肝转移患者均应考虑肝增强MRI。

研究设计与样本

  • 国际、多中心、前瞻性、增量诊断准确性试验,在荷兰、比利时、挪威和意大利的14个肝脏手术中心开展。
  • 纳入年龄≥18岁、组织学证实结直肠癌、WHO体能状态评分0-4分、基于增强CT计划局部治疗的原发或复发性结直肠癌肝转移患者。
  • 所有患者在当地治疗前均接受增强CT和肝增强MRI(含弥散加权成像,以钆塞酸二钠为对比剂)。
  • 主要结局为基于肝增强MRI结果局部临床治疗计划(由各中心决定)的改变,在意向成像人群中分析。
  • 局部治疗计划改变比例的minimal clinically important difference为10%。

主要发现

  • 2019年12月17日至2021年7月31日,评估325例结直肠癌肝转移患者的资格,298例入组并纳入意向治疗人群,其中男性177例(59%)、女性121例(41%)。
  • 基于肝增强MRI结果,298例中92例(31%;95% CI 26-36)的局部治疗计划发生改变。
  • 40例(13%)需要更广泛的局部治疗,11例(4%)需要更小范围的局部治疗。
  • 34例(11%)撤销了治愈性局部治疗指征,其中26例(9%)为病变过于广泛,8例(3%)为肝增强MRI显示良性病变(中位随访21.0个月[IQR 17.5-24.0]确认)。

关键数值与推荐

  • 局部治疗计划改变比例的minimal clinically important difference为10%。
  • 局部治疗计划改变比例:92/298(31%;95% CI 26-36)。
  • 需更广泛局部治疗:40/298(13%);需更小范围局部治疗:11/298(4%);撤销治愈性局部治疗指征:34/298(11%)。
  • 撤销指征中病变过于广泛:26/298(9%);肝增强MRI显示良性病变:8/298(3%)。

临床怎么用

  • 作者认为,所有基于增强CT计划接受局部治疗的结直肠癌肝转移患者均应考虑肝增强MRI。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Guidelines are inconclusive on whether contrast-enhanced MRI using gadoxetic acid and diffusion-weighted imaging should be added routinely to CT in the investigation of patients with colorectal liver metastases who are scheduled for curative liver resection or thermal ablation, or both. Although contrast-enhanced MRI is reportedly superior than contrast-enhanced CT in the detection and characterisation of colorectal liver metastases, its effect on clinical patient management is unknown. We aimed to assess the clinical effect of an additional liver contrast-enhanced MRI on local treatment plan in patients with colorectal liver metastases amenable to local treatment, based on contrast-enhanced CT. METHODS: We did an international, multicentre, prospective, incremental diagnostic accuracy trial in 14 liver surgery centres in the Netherlands, Belgium, Norway, and Italy. Participants were aged 18 years or older with histological proof of colorectal cancer, a WHO performance status score of 0-4, and primary or recurrent colorectal liver metastases, who were scheduled for local therapy based on contrast-enhanced CT. All patients had contrast-enhanced CT and liver contrast-enhanced MRI including diffusion-weighted imaging and gadoxetic acid as a contrast agent before undergoing local therapy. The primary outcome was change in the local clinical treatment plan (decided by the individual clinics) on the basis of liver contrast-enhanced MRI findings, analysed in the intention-to-image population. The minimal clinically important difference in the proportion of patients who would have change in their local treatment plan due to an additional liver contrast-enhanced MRI was 10%. This study is closed and registered in the Netherlands Trial Register, NL8039. FINDINGS: Between Dec 17, 2019, and July 31, 2021, 325 patients with colorectal liver metastases were assessed for eligibility. 298 patients were enrolled and included in the intention-to-treat population, including 177 males (59%) and 121 females (41%) with planned local therapy based on contrast-enhanced CT. A change in the local treatment plan based on liver contrast-enhanced MRI findings was observed in 92 (31%; 95% CI 26-36) of 298 patients. Changes were made for 40 patients (13%) requiring more extensive local therapy, 11 patients (4%) requiring less extensive local therapy, and 34 patients (11%) in whom the indication for curative-intent local therapy was revoked, including 26 patients (9%) with too extensive disease and eight patients (3%) with benign lesions on liver contrast-enhanced MRI (confirmed by a median follow-up of 21·0 months [IQR 17·5-24·0]). INTERPRETATION: Liver contrast-enhanced MRI should be considered in all patients scheduled for local treatment for colorectal liver metastases on the basis of contrast-enhanced CT imaging. FUNDING: The Dutch Cancer Society and Bayer AG - Pharmaceuticals.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Görgec B, Hansen IS, Kemmerich G, et al. MRI in addition to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO): an international, multicentre, prospective, diagnostic accuracy trial. Lancet Oncol. 2023. PMID: 38081200. doi:10.1016/S1470-2045(23)00572-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。